Biogen is an American biotech company based in Cambridge, Massachusetts. The company uses recombinant DNA technology, also known as biotechnology. This makes it possible to produce human proteins and therefore medicinal products with the help of microorganisms. The company continues to develop new substances and works on improving already approved molecules.
According to Biogen's latest financial reports the company's total debt is โฌ5.82 Billion. A companyโs total debt is the sum of all current and non-current debts.
Year | Total debt | Change |
---|---|---|
2024-12-31 | โฌ6.37 B | -4.02% |
2023-12-31 | โฌ6.63 B | 7.66% |
2022-12-31 | โฌ6.16 B | -8.16% |
2021-12-31 | โฌ6.71 B | 5.49% |
2020-12-31 | โฌ6.36 B | 11.97% |
2019-12-31 | โฌ5.68 B | 9.54% |
2018-12-31 | โฌ5.18 B | 4.85% |
2017-12-31 | โฌ4.94 B | -20.13% |
2016-12-31 | โฌ6.19 B | 3.81% |
2015-12-31 | โฌ5.96 B | 1144.31% |
2014-12-31 | โฌ0.47 B | 11.17% |
2013-12-31 | โฌ0.43 B | -49.97% |
2012-12-31 | โฌ0.86 B | 5.25% |
2011-12-31 | โฌ0.81 B | -9.44% |
2010-12-31 | โฌ0.90 B | 17.85% |
2009-12-31 | โฌ0.76 B | -3.57% |
2008-12-31 | โฌ0.79 B | -25.62% |
2007-12-31 | โฌ1.07 B | 1360.75% |
2006-12-31 | โฌ73.28 M | 99.82% |
2005-12-31 | โฌ36.67 M | -94.15% |
2004-12-31 | โฌ0.62 B | -11.05% |
2003-12-31 | โฌ0.70 B | -14.95% |
2002-12-31 | โฌ0.82 B | 1450.92% |
2001-12-31 | โฌ53.42 M | -53.96% |
2000-12-31 | โฌ0.11 B | 3.28% |
1999-12-31 | โฌ0.11 B | 65.98% |
1998-12-31 | โฌ67.69 M | -12.26% |
1997-12-31 | โฌ77.14 M | 38.15% |
1996-12-31 | โฌ55.84 M |